Plasma Lipoproteins and Atherosclerosis Accomplishments and Opportunities by Havel, Richard J.
Cell
152
acids present in dietary fat (triacylglycerols). Animal fatsPlasma Lipoproteins
rich in saturated long-chain fatty acids and cholesteroland Atherosclerosis: raise the concentration of lipoproteins containing apoli-
poprotein B-l00 by downregulating low-density lipopro-Accomplishments
tein (LDL) receptors in hepatic parenchymal cells. Theseand Opportunities
lipoproteins are not only synthesized but also largely
undergo terminal catabolism in these cells. Controversy
Advances in Vascular BiologyÐVolume 5: is continuing as to whether the amount of total dietary
Plasma Lipids and Their Role in Disease fatty acids or only that of saturated fatty acids should
Edited by Philip J. Barter be reduced. Also, plasma lipids are affected differently
and Kerry-Anne Rye by n-6 as opposed to n-3 polyunsaturated fatty acids.
(Series Editors, M. A. Vadas and J. Harlan) Studies analyzing electrophysiologic effects on myo-
Amsterdam: Harwood Academic Publishers cytes indicate that dietary intake of n-3 fatty acids may
(1999). 368 pp. $120.00 prevent fatal cardiac arrhythmias induced by ischemia
(Kang and Leaf, 2000). These and related topics central
to prevention and treatment of atherosclerotic diseaseIn one sense, the topic of plasma lipids and their role
receive little or no consideration.in disease is a mature field of biomedical investigation,
The dramatically reduced incidence of heart attackswith successful clinical applications to diagnosis, pre-
and strokes due to plasma lipid±lowering drugs invention, and treatment. At the same time, the field is still
healthy persons as well as those affected by athero-advancing rapidly, particularly with the use of transgenic
sclerotic complications is addressed only briefly in sev-models of disease that are illuminating important funda-
eral chapters. The relationship between lipid-loweringmental and clinical issues and the consistent evidence
and the clinical benefits of treatment with b-hydroxythat plasma lipid-lowering has salutary effects in a vari-
b-methyl coenzyme A reductase inhibitors known asety of clinical settings. As indicated in the editors' pref-
ªstatinsº is somewhat controversial. Direct effects oface to this text, abnormalities of plasma lipid transport
these drugs on vascular function have been proposedªreflect an interaction between genes and a variety of
to account for the impressive clinical benefits of statinlifestyle factors,º several of which ªlead to severe clinical
therapy that seem to outweigh effects upon lipid-low-disease.º Thus, they direct this multiauthored text to
ering. Even greater benefit may, however, accrue frominterested physicians as well as scientists.
a procedure known as ªLDL apheresis,º whereby lipo-Plasma lipids are carried mainly in macromolecular
proteins containing apolipoprotein B are selectively re-complexes known as lipoproteins, in which nonpolar
moved by absorption onto affinity reagents (Kajinamilipids are shielded from the aqueous environment by
and Mabuchi, 1999). Also, the mechanism of action ofpolar lipids and specific proteins (apolipoproteins). A
drugs of the ªfibrateº class is currently receiving muchnotable exception is the albumin±fatty acid complex.
attention. Fibrates are used to reduce the concentrationNonesterified (free) fatty acids bound to albumin repre-
of plasma triacylglycerols, by increasing efficiency of
sent large amounts of energy-rich, readily oxidizable
the catabolism of triacylglycerol-rich very low-density
lipid carried through the plasma, mainly from adipose
lipoproteins (VLDL); these compounds cause hypertro-
cells to muscle and liver. Although this book is con-
phy and hyperplasia of peroxisomes in rodent liver. Re-
cerned with plasma lipids and disease, little attention is cent studies have shown that they act by stimulating
paid to altered rates of free fatty acid transport that are the production of peroxosime proliferator activator re-
central to several secondary dyslipoproteinemias, such ceptors (PPARs), thereby reducing the synthesis of cer-
as in diabetes mellitus. Abnormalities of free fatty acid tain apolipoproteins in liver and increasing that of lipo-
transport also contribute to lipoprotein abnormalities protein lipase in adipose tissue (Schoonmans et al.,
associated with obesity and perhaps with certain pri- 1997). PPARs and their regulation, which have broad
mary disorders of plasma lipoproteins, such as familial implications for the regulation of lipoprotein±lipid me-
combined hyperlipidemia. The related and controversial tabolism, are hardly mentioned.
issue of acylation-stimulating protein (complement fac- This volume begins with two introductory overview
tor 3 desarg), genetic abnormalities of which have been chapters on normal plasma lipoprotein transport and
proposed to cause hyperapobetalipoproteinemia by in- metabolism and dyslipidemias, followed by a review of
creasing the flux of free fatty acids into the liver (Kilds- population and family evidence relating plasma lipids
gaard et al., 1999), is ignored. and lipoprotein concentrations to atherosclerotic dis-
Even more surprising in a book directed in part to ease. Most of the other chapters deal with atherogenic
physicians is the paucity of material on nutritional influ- and antiatherogenic lipoproteins and their receptors,
ences on plasma lipids and disease. Atherosclerotic dis- and with lipases and lipid-transfer proteins. There are
ease, the major cause of death in Western countries, also chapters on apolipoprotein E (treating not only
is directly related to plasma cholesterol concentration. plasma lipoproteins but also the role of the role of apoli-
Among the world's populations, plasma cholesterol var- poprotein E produced in the central nervous system in
ies widely and is influenced primarily by diet. Indeed, it Alzheimer's disease), on lipid/lipoprotein oxidation, and
is generally held that differences in dietary patterns are on endothelial function in dyslipoproteinemias.
the primary cause of the observed several-fold differ- Two chapters on atherogenic lipoproteins address the
ences in coronary heart disease mortality among the extensively investigated subject of chylomicron rem-
world's populations. The major dietary components re- nants and LDL. The latter is concise, but reasonably
comprehensive in considering important differencessponsible for these differences are the long-chain fatty
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among species of LDL differing in size and density, po- a-tocopherol can promote rather than prevent lipid per-
tentially atherogenic modifications including lipid-oxi- oxidation under circumstances that may be biologically
dation, and the role of LDL in formation of arterial fatty relevant is well documented.
streaks and complicated plaques. The former presents The final chapter discusses effects of plasma lipopro-
an enthusiast's view of the importance of chylomicron teins on endothelial function, mainly related to the ca-
remnants in atherogenesis, focusing primarily on the pacity to generate NO. This is a welcome addition to
author's work. The chapter contains numerous contro- such a book, but one might have hoped for an additional
versial statements such as the suggestion that as much chapter on lipoproteins and thrombosis, and more in-
as 15 g of cholesterol may be transported in plasma depth discussion of the role of lipoproteins in athero-
chylomicrons daily, and that chylomicron remnants are sclerotic plaque-rupture and stabilization. A compilation
a ªprimaryº atherogenic lipoprotein. The author of this of reviews covering this rapidly moving field is useful,
chapter correctly points out that humans are in a post- but the discerning reader will have to search elsewhere
prandial (variably chylomicronemic) state most of the for up-to-date consideration of a number of important
time, but fails to note that postprandial changes in liver- aspects of plasma lipids and disease.
derived VLDL are more pronounced. Although there is
considerable evidence for the atherogenicity of certain Richard J. Havel
subfractions of VLDL, neither in this chapter nor else- Cardiovascular Research Institute
where in this volume is this topic discussed. University of California, San Francisco
Two chapters on high-density lipoproteins (HDL) and San Francisco, California 94143
their receptors provide useful summaries of these im-
portant topics. That the antiatherogenic property of HDL References
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Mol. Immunol. 36, 869±876.leads to storage of cholesteryl esters in reticuloendothe-
Schoonjans, K., Martin, G., Staels, B., and Auwerx, J. (1997). Curr.lial cells and extremely low levels of circulating HDL
Opin. Lipidol. 8, 159±166.(Hobbs and Rader, 1999).
Zambon, A., Hokanson, J.E., Brown, B.B., Brunzell, J.D. (1999). Cir-Three well-written chapters address lipid-transfer pro-
culation 99, 1959±1964.
teins: microsomal triglyceride transfer protein, plasma
cholesteryl ester transfer protein (CETP) and phospho-
lipid transfer protein (PLTP). The discussion of settings
in which CETP may be pro- or antiatherogenic is particu-
larly insightful. The role of PLTP, which has been difficult Understanding Sex in the Brain
to assess, has become clearer from recent observations
on PLTP knockout mice. These animals display greatly
Drive: Neurobiological and Molecular Mechanismsreduced HDL levels and other abnormalities consistent
of Sexual Motivationwith impaired transfer of polar lipids from VLDL and
By Donald Pfaffchylomicrons to HDL (Jiang et al., 1999).
Cambridge, MA: MIT Press (1999). 316 pp. $90.00The chapter on endothelial lipases affecting plasma
lipid transport provides a useful introduction to this
Sexual motivation has always been a hot topic of scien-topic. However, the emerging roles of hepatic lipase in
tific and cultural interest. Thousands of years of humanremodeling of LDL and well as HDL species, relevant to
history have been spent trying to understand and manip-atherosclerotic disease (Zambon et al., 1999) deserve
ulate it. We have lusted after it in the form of drugs,more emphasis.
potions, glands, scents, clothing, fetish objects, music,The authoritative chapter on apolipoprotein E is more
lighting, and correct phrases. Earlier this century, pio-comprehensive in considering several complex issues.
neers like Steinach, Stone, Young, Boling, Blandau, andTerminology in this field can be confusing, even to those
Beach found part of it in the secretions of gonadal tis-working in it. In this chapter, terms such as sequestra-
sues, the steroid hormones testosterone, estrogen, andtion, trapping, docking, and receptor binding are not
progesterone. Later, Beach, Davidson, Larsson, andalways well defined. Here, heparan sulfate proteogly-
SoÈ dersten found that gonadal steroids not only maintaincans are elevated to the status of a receptor, although
the function of peripheral tissues, but act on the braintheir role in clearance of remnant lipoproteins is stated
to change the motivational state of the organism. By theto be one of sequestration. By contrast, hepatic lipase,
late 1960s, research into the nature of steroid hormonewhich may also sequester chylomicron remnants is here
action in the brain had blossomed into the discipline ofrelegated to a secondary, processing role. Oxidation of
neuroendocrinology; one of the founders of this disci-plasma lipids and apolipoproteins is the subject of a
scholarly treatise in which the authors' evidence that pline was Donald Pfaff.
